Cowpox Virus Protein CPXV012 Eludes CTLs by Blocking ATP Binding to TAP


*J Immunol* published online 14 July 2014

http://www.jimmunol.org/content/early/2014/07/13/jimmunol.1400964
Cowpox Virus Protein CPXV012 Eludes CTLs by Blocking ATP Binding to TAP

Rutger D. Luteijn,* Hanneke Hoelen,* Elisabeth Kruse,* Wouter F. van Leeuwen,* Jennine Grootens,* Daniëlle Horst,* Martijn Koorengevel,† Jan W. Drijfhout,‡ Elisabeth Kremmer,§ Klaus Früh,¶ Jacques J. Neefjes,‖ Antoinette Killian,‖ Robert Jan Lebbink,* Maaieke Ressing,*1 and Emmanuel J. H. J. Wiertz*

CD8+ CTLs detect virus-infected cells through recognition of virus-derived peptides presented at the cell surface by MHC class I molecules. The cowpox virus protein CPXV012 deprives the endoplasmic reticulum (ER) lumen of peptides for loading onto newly synthesized MHC class I molecules by inhibiting the transporter associated with Ag processing (TAP). This evasion strategy allows the virus to avoid detection by the immune system. In this article, we show that CPXV012, a 9-kDa type II transmembrane protein, prevents peptide transport by inhibiting ATP binding to TAP. We identified a segment within the ER-luminal domain of CPXV012 that imposes the block in peptide transport by TAP. Biophysical studies show that this domain has a strong affinity for phospholipids that are also abundant in the ER membrane. We discuss these findings in an evolutionary context and show that a frameshift deletion in the CPXV012 gene in an ancestral cowpox virus created the current form of CPXV012 that is capable of inhibiting TAP. In conclusion, our findings indicate that the ER-luminal domain of CPXV012 inserts into the ER membrane, where it interacts with TAP. CPXV012 presumably induces a conformational arrest that precludes ATP binding to TAP and, thus, activity of TAP, thereby preventing the presentation of viral peptides to CTLs. The Journal of Immunology, 2014, 193: 000–000.
whereas UL49.5 of equid herpesvirus (EHV)-1 and EHV-4 interfere with ATP binding to the NBDs of TAP (14). BNFL2a of EBV blocks both peptide and ATP binding to TAP (16). Inhibition of TAP-mediated peptide transport was considered to be unique to herpesviruses until the recent identification of the cowpox virus (CPXV) protein CPXV012 as an effective inhibitor of peptide transport by TAP (17, 18).

CPXVs are members of the Orthopoxvirus genus, which comprises several clinically and economically important pathogens, including variola virus (the causative agent of smallpox), camelpox virus, and monkeypox virus. CPXVs have the largest genome of all orthopoxviruses and encode an elaborate arsenal of immune-evasion proteins (19). Two of these proteins, CPXV012 and CPXV203, prevent cytotoxic T cell recognition by interfering with MHC I-mediated Ag presentation. CPXV012 inhibits Ag presentation by retaining MHC I/peptide complexes in the ER (20). CPXV023 acts through a KDEL-related KTEL ER-retention motif encoded in its C-terminal domain (20). Deletion of CPXV023 from CPXV only partially restored MHC I surface expression, suggesting the presence of an additional mechanism that is active in MHC I suppression. Indeed, CPXV012 was identified as the second CPXV protein to interfere with MHC I Ag presentation (17, 18). Deletion of both CPXV012 and CPXV203 fully restored MHC I surface levels. Ex vivo, T cells isolated from CPXV-infected mice produced INF-γ upon stimulation with CPXVΔ012Δ203-infected cells, in contrast with wild-type CPXV-infected cells (18). Furthermore, in vivo experiments showed that mice infected with the wild-type virus succumbed to virus infection (18).

CPXV012 specifically abrogates TAP-mediated peptide translocation through an unknown mechanism, thereby depriving the ER of peptides (17, 18). In this article, we show that CPXV012 inhibits TAP through its ER-luminal domain by interfering with ATP binding to the cytosolic NBDs of TAP. We define the regions within the CPXV012 ER-luminal domain that are critical for inhibition of TAP function and downregulation of MHC I expression. The ER-luminal domain of CPXV012 adopts an α-helical structure in the presence of phospholipids and displays a strong affinity for ER membranes. The ER-luminal domain of CPXV012 binds to TAP and arrests the TAP complex in a conformational state that is unable to acquire energy (ATP), thereby inhibiting the translocation of peptides into the ER. Additionally, we provide an explanation for the emergence of the functional ER domain of CPXV012 in evolution, via the acquisition of a frameshift mutation in the ancestral protein of CPXV012.

Materials and Methods
Cell lines
The human melanoma cell line MelJuSo (MJS) (21) was maintained in RPMI 1640 medium (Invitrogen), supplemented with 10% FCS (PAA Laboratories), 2 mM t-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (complete medium). HEK293T cells used for lentivirus production were maintained in DMEM complete medium (Invitrogen). HEK293T cells used for lentivirus production were maintained in DMEM complete medium (Invitrogen). HEK293T cells used for lentivirus production were maintained in DMEM complete medium (Invitrogen). HEK293T cells used for lentivirus production were maintained in DMEM complete medium (Invitrogen). HEK293T cells used for lentivirus production were maintained in DMEM complete medium (Invitrogen).

Lentivirus and retrovirus production and transduction
A plasmid encoding codon-optimized CPXV012 from CPXV strain Brighton Red with a FLAG-tag at the N terminus (CPXV012) was used as a template for PCR amplification with the primers 5'-CGGGATCCACGAGCTCAAA-3' and 5'-GCCGTGATCATCATGATGTCG-3'. The resulting PCR product was cloned into the pLZRS retroviral vector. EBV-derived BNFL2a with a C-terminal HA tag (BNFL2a) was cloned into the retroviral vector pLZRS, as described previously (16). Genes were cloned upstream of an internal ribosomal entry site (IRES) to allow coexpression of the truncated nerve growth factor receptor (ΔNGFR) as a marker.

CPXV012 and CPXV012 variants were cloned into the lentiviral vector pLV upstream of IRES and eGFP, as described previously (17). For the production of replication-deficient recombinant retroviruses, pLZRS vectors were transfected into φNX-A packaging cells. MJS cells were transduced with retrovirus, as described previously (23). Cells were FACS sorted to achieve expression of the gene of interest in all cells. For the production of replication-deficient recombinant lentivirus, the lentiviral vector and third-generation packaging vectors pVSVG, pMDL, and pRSV were cotransfected into HEK293T cells. Lentivirus-containing supernatants were harvested after 3 d of virus production and used to transduce MJS cells by spin infection at 1000 × g for 2 h at 33°C in the presence of 3.2 mg/ml polybrene. MJS cells transduced with retrovirus or lentivirus were sorted by flow cytometry (FACS Aria II; BD Biosciences).

CPXV012 variants
CPXV012 deletion and substitution variants were generated and cloned into the pLV-IRES eGFP lentiviral vector. For cloning purposes, a silent mutation resulting in an XhoI restriction site was introduced into CPXV012 using primers 1 and 2 (Table I). The following primers (Table I) were used to generate the CPXV012 deletion and substitution variants: primers 2 and 3 for CPXV012Δcyt, primers 4 and 5 for CPXV012ΔER, primers 2 and 6 for CPXV012 soluble, primers 7–10 for TIR-CPXV012, primers 2 and 11 for CPXV012-Ala1, primers 2 and 12 for CPXV012-Ala2, primers 2 and 13 for CPXV012-Ala3, primers 4 and 14 for CPXV012-Ala4, primers 4 and 15 for CPXV012-Ala5, primers 2 and 16 for CPXV012-Ala6, and primers 2 and 17 for CPXV012-Ala7.

To ensure proper ER localization of the CPXV012-soluble variant, we replaced the endogenous signal sequence of CPXV012 with the (cleavable) human CD8 signal sequence (24), because CPXV012 is a type II protein with the TM domain acting as a signal sequence. The chimic protein transferrin receptor (TIR)-CPXV012 was constructed, in which the ER-luminal domain of CPXV012 was fused to amino acid residues 58–88 of the type II TIR. This region in TIR includes part of the cytosolic tail (aa 58–67) and the TM domain (aa 68–88) (25). The two cysteine residues flanking the TIR TM domain were replaced by alanine residues to remove a potential localization and dimerization signal (25). All variants were produced from a bicistronic transcript, encoding CPXV012 followed by an IRES and eGFP.

Ab generation
The CPXV012-specific rat IgG2a mAb 2A8 was generated by immunizing Lou/C rats with OVA-coupled peptide encompassing CPXV012 aa 28–44 (sequence: CSMEHG YFQEGISRFK).

Abs
The following primary and directly conjugated Abs were used: mouse anti-HLA class I HC HC10 mAb, PE-conjugated mouse anti–HLA-A/B/C (BD/62) (BD Serotec; mAb; #MCA15PE); PE-conjugated mouse anti–HLA-DR mouse G46-6 mAb (BD Pharmingen; #347401), mouse anti-calnexin AF8 mAb (kindly provided by M. Brenner, Harvard Medical School, Boston, MA), mouse anti-FLAG M2 mAb (Sigma-Aldrich; #F1804), rabbit anti-tapasin gp48-C (provided by P. Cresswell, Yale School of Medicine, New Haven, CT), rat anti-tapasin F6 mAb (provided by R. Tampé, Johann Wolfgang Goethe University, Frankfurt/Main, Germany), mouse anti-TAP1 148.3 mAb (provided by R. Tampé), mouse anti-14TAP 435.4 mAb (provided by P. van Endert, Hospital Necker, Paris, France), rat anti-CNX012 2A8 mAb, rat anti-GFP RQ2 mAb (MBL; #D153-3), mouse anti-GFP IE4 mAb (Enzo; #ADI-SAB-500), mouse anti-CD71 (TIR- H6.4) (Invitrogen; #1368xx), and biotin-conjugated mouse anti-NGFR mAb (BD; #557195).

The following secondary Abs were used: HRP-conjugated rabbit anti-rat IgG (DAKO, #P0450), HRP-conjugated goat anti-rat IgG L-chain specific (Jackson ImmunoResearch, #112-035-175), HRP-conjugated goat anti-mouse IgG L-chain specific (Jackson ImmunoResearch, #115-035-174), HRP-conjugated goat anti-mouse IgG (Bio-Rad; #172-1011), and allophycocyanin-conjugated streptavidin (BD Pharmingen; #554067).

Coinmunoprecipitation and immunoblotting
Cells were lysed in 0.5% Nonidet P-40 (NP-40) buffer (0.5% NP-40, 50 mM Tris-HCl [pH 7.5], and 5 mM MgCl2) or 1% digitonin buffer (1% digitonin, 50 mM Tris-HCl [pH 7.5], 5 mM MgCl2, and 150 mM NaCl) in the presence of 10 μM leupeptin and 1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride. To remove nuclear fractions, cell lysates were centrifuged at
12,000 × g at 4˚C for 20 min. For coimmunoprecipitation experiments, postnuclear digitonin lysates were incubated with protein G-Sepharose beads (GE Healthcare) and the Abs indicated. After overnight incubation at 4˚C, samples were washed four times in 0.5% digitonin buffer, and bound fractions were resuspended in TE buffer (20 mM Tris [pH 8.0] and 1 mM EDTA).

To prepare samples for SDS-PAGE separation, coimmunoprecipitation samples and NP-40 postnuclear lysates were boiled in Laemmli sample buffer at 95˚C for 5 min. After SDS-PAGE, proteins were transferred to polyvinylidene difluoride membranes with ECL (Thermo Scientific Pierce) and exposure to Amersham Hyperfilm (GE Healthcare).

Flow cytometry

MHC I and MHC class II (MHC II) cell surface expression was measured by flow cytometry. All washing and Ab-incubation steps were performed in PBS, supplemented with 0.5% BSA and 0.02% sodium azide. For MHC I cell surface expression, cells were incubated with PE-conjugated W6/32 mAb. For MHC II cell surface expression, cells were incubated with PE-conjugated G46-6 Ab. Cells were fixed using 1% formaldehyde in PBS, supplemented with 0.5% BSA and 0.02% sodium azide. For MHC I and MHC class II (MHC II) cell surface expression was measured by flow cytometry. All washing and Ab-incubation steps were performed in PBS supplemented with 0.5% BSA and 0.02% sodium azide. For MHC I cell surface expression, cells were incubated with PE-conjugated W6/32 Ab. For MHC II cell surface expression, cells were incubated with PE-conjugated G46-6 Ab. Cells were fixed using 1% formaldehyde in PBS supplemented with 0.5% BSA and 0.02% sodium azide, and flow cytometric parameters were recorded using a FACSCanto II (BD Biosciences). Analysis of flow cytometry data was performed using FlowJo software (TreeStar).

Peptides

Synthetic peptides were prepared by normal Fmoc chemistry using pre-loaded Tentagel resins, using PyBop/N-methylmorpholine for in situ activation and 20% piperidine in N-methylpyrrolidinone for Fmoc removal (26). Couplings were performed for 75 min. After final Fmoc removal, peptides were cleaved with trifluoroacetic acid/H₂O 19:1 containing additional scavengers when C or W residues were present in the peptide sequence. Peptides were isolated by ether/pentane precipitation. Peptides were analyzed for purity using reversed-phase HPLC with ECL (Thermo Scientific Pierce) and exposure to Amersham Hyperfilm (GE Healthcare).

MALDI-TOF mass spectrometry. All other peptides were synthesized with an N-terminal biotin moiety and a C-terminal amide. Cysteines were replaced by the isosteric α-amino-n-butyric acid.

**Peptide-transport assay**

The peptide-transport assay was performed as described (27). Control MJS cells or MJS cells expressing CPXV012 wild-type or CPXV012 variants were permeabilized with streptolysin O (Murex Diagnostics) and incubated with the fluorescein-coupled peptide CVNKTERAY (N-linked glycosylation site underlined) in the presence or absence of 10 mM ATP at 37˚C for 10 min. Cells were subsequently lysed in Triton X-100 buffer (1% Triton X-100, 500 mM NaCl, 2 mM MgCl₂, 50 mM Tris-HCl [pH 8]) and centrifuged at 12,000 × g at 4˚C for 20 min to remove nuclei and debris. To evaluate peptide transport into the ER, postnuclear lysates were incubated with ConA-Sepharose beads (GE Healthcare), and glycosylated peptides were isolated from the lysate. After washing the beads with the first-wash buffer (0.1% Triton X-100, 500 mM NaCl, 2 mM MgCl₂, 50 mM Tris-HCl [pH 8]), the second-wash buffer (500 mM NaCl, 50 mM Tris-HCl [pH 8]), peptides were eluted from beads using elution buffer (50 mM mannopyranoside, 10 mM EDTA, 50 mM Tris-HCl [pH 8]), and fluorescent peptides were detected using a FLUOstar Omega (BMG LABTECH) fluorescence plate reader.

**ATP-binding assay**

The ATP-binding assay was performed as described previously (16). Briefly, control MJS cells or MJS cells expressing BLNF2a or CPXV012 were lysed in 1% digitonin lysis buffer, as described for coimmunoprecipitation and immunoblotting experiments. Cell lysates were centrifuged at 12,000 × g at 4˚C for 20 min to remove nuclei. Postnuclear lysates were incubated with hydrated C-8 ATP-agarose beads (13 μM final concentration, Sigma-Aldrich) at 4˚C for 2 h. Unbound supernatant was collected, and ATP-bound proteins were eluted from the beads with 500 mM EDTA (ATP-bound fraction). The ATP-bound fraction and unbound supernatant were analyzed for protein content by immunoblotting with the Abs indicated.

**Peptide-binding assay**

Peptide binding was evaluated as described previously (16). MJS cells stably transfected with TAP1-eGFP and transduced with control retrovirus or retroviruses expressing BLNF2a or CPXV012 were homogenized using a cell cracker (European Molecular Biology Laboratory; chamber 8.020 mm, ball 8.006 mm) to obtain TAP-containing microsomes. These microsomes were incubated with the 125I-labeled peptide 5PS2 (ERYDKSE-[BPA]-L)
 containing a photoactivatable biophenol A cross-linker (28). After incubation on ice for 15 min, the microsomes were washed with PBS, and peptide was covalently linked to binding partners by UV exposure for 10 min on ice using a UVP device (Blak-Ray B-100A) with a mercury lamp (PAR38; Sylvania). Microsomes were lysed in 0.5% CHAPS buffer (0.5% CHAPS, 100 mM Tris-HCl [pH 8], 5 mM MgCl2), and TAP1-eGFP was isolated using the anti-GFP RQ2 mAb and Protein G beads. Samples were separated by SDS-PAGE, as described above, and 125I-labeled peptide binding was visualized by phosphoimaging. A fraction of the unlabeled microsomes was used for immunoblotting with the anti-GFP 1E4 primary Ab and HRP-conjugated anti-mouse IgG secondary Ab.

**Preparation of large unilamellar vesicles and circular dichroism**

Preparation of large unilamellar vesicles (LUVs) and circular dichroism (CD) spectrum recording were performed as described previously (29). LUVs composed of a mixture of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phospho-rac-1-serine (DOPS) (Avanti Polar Lipids) in a 7:3 molar ratio were prepared from 5-mM stock solutions of DOPC and DOPS in chloroform in a glass tube. The solvent was evaporated with nitrogen gas, and the resulting lipid film was kept in a vacuum desiccator for 20 min. Lipid films were hydrated in 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 6.2) at a lipid concentration of 5 mM for 30 min. The lipid suspensions were freeze-thawed for 20 cycles at temperatures of approximately −196 and 40°C and subsequently extruded 20 times through 0.2-μm pore size filters (Anotop 10; Whatman, Maidstone, U.K.). A total of 625 μM LUVs and/or 20 μM peptides diluted in 10 mM MES buffer (pH 6.2) were used for measurements. CD spectra were recorded on a Jasco 810 spectropolarimeter (Jasco, Easton, MD) over a wavelength range of 200–250 nm. Measurements were recorded every 1 nm at a scan rate of 20 nm/min at room temperature in cuvettes with a path length of 1.0 mm. Each reported spectrum is the average of five independent scans.

**Langmuir monolayer**

Peptide-induced changes in the surface pressure of a monomolecular layer (monolayer) of phospholipids at a constant surface area were measured using the Wilhelmy plate method (29). A Teflon trough was filled with 50 ml PBS (pH 7.4). The buffer below the monolayer (subphase) was continuously stirred during the measurements. Lipid monolayers were spread from a 1-mM stock solution in chloroform at the air–buffer interface to give an initial surface pressure of 35 mN/m, before 25 μl of a 55-μM freshly prepared stock solution of peptide in DMSO was injected into the subphase, resulting in a final peptide concentration of 0.3 μM.

**Results**

**CPXV012 interacts with an intact MHC class I PLC**

CPXV protein CPXV012 impairs MHC I surface expression by inhibiting TAP-mediated peptide transport (17, 18). However, the molecular mechanism that underlies this TAP inhibition is unknown. To study the biochemical and functional characteristics of CPXV012, the viral protein was equipped with an N-terminal FLAG tag and expressed in the human melanoma cell line MJS using lentiviral transduction. As expected, TAP-mediated translocation of the FLAG-tagged CPXV012 is functional and selective for MHC I (compare lanes 1 and 6), indicating that the FLAG-tagged CPXV012 is functional and selective for MHC I in MJS cells.

To test whether CPXV012 influences the composition of the PLC, individual PLC constituents were isolated from cells lysed in the presence of digitonin to preserve the interactions within the PLC (Fig. 1B). CPXV012 was found to interact with the complex and did not seem to disturb the overall integrity of the PLC, because similar amounts of TAP1, TAP2, and tapasin were coisolated in the presence and absence of CPXV012 (Fig. 1B, compare lanes 1 and 2 and lanes 5 and 6). In the presence of CPXV012, the PLC was enriched for MHC I (compare lanes 1 and 2 and lanes 5 and 6).

**FIGURE 1.** CPXV012 interacts with an intact PLC. (A) TAP-mediated peptide transport is affected by CPXV012 (upper panel). Transport of a fluorescently labeled peptide was measured in MJS cells expressing control vector or CPXV012. To distinguish between active transport and passive diffusion, transport was measured in the presence and absence of ATP. Active transport in cells expressing CPXV012 was compared with transport in control cells expressing eGFP vector only, which was set at 100%. Mean ± SEM from three independent experiments is shown. CPXV012 specifically decreases MHC I surface expression (lower panels). Flow cytometric analysis of MHC I and MHC II surface expression on the human melanoma cell line MJS stably expressing CPXV012 (black line) or control vector (gray line). The W6/32 mAb was used for detection of MHC I, and the HLA-DR–specific G46-6 mAb was used for the detection of MHC II. Flow cytometry results are representative of at least three independent experiments. (B) CPXV012 interacts with the PLC. TAP1 (mAb 148.3), TIR (mAb H68.4), tapasin (Tpsn; mAb gp48-C), or MHC I (mAb HC10) were immunoprecipitated from digitonin lysates of MJS cells expressing CPXV012 (lanes 1–7) or control vector (lanes 8–10). Immunoprecipitated proteins were immunoblotted for TAP1 (mAb 148.3), TAP2 (mAb 435.4), tapasin (mAb 7F6), and MHC I (mAb HC10), as shown. Lanes 1 and 2 show input levels of indicated proteins prior to immunoprecipitation. A shorter exposure time was used for lanes 7 and 8 of the immunoblot for MHC I, as well as for lanes 9 and 10 of the immunoblots for TAP1, tapasin, MHC I, and CPXV012. Immunoblots are representative of three independent experiments.
and 6). In agreement with this, more TAP1, TAP2, and tapasin coimmunoprecipitated with MHC I in CPXV012-expressing cells compared with control cells (compare lanes 7 and 8). This suggests that peptide loading of MHC I is obstructed by CPXV012, thus delaying the release of MHC I from the PLC.

The interactions between CPXV012 and the components of the PLC were specific, because TIR, an unrelated TM protein, and MHC II (data not shown) were not coisolated. Conversely, isolation of TIR did not yield any PLC proteins (Fig. 1B, lanes 3 and 4).

In conclusion, CPXV012 interacts with the PLC in the ER. CPXV012 does not affect the organization of the core components of the PLC (TAP1, TAP2, and tapasin); MHC I appears to accumulate in the PLC, likely as the result of diminished peptide supply.

**CPXV012 interferes with ATP binding to TAP**

Peptide translocation by TAP can be blocked by viral TAP inhibitors at different stages during the peptide-translocation cycle (30). This cycle initiates with the binding of peptide to the cytosolic peptide-binding domain of TAP, which allows subsequent ATP binding to the cytosolic NBDs (31). ATP binding and hydrolysis at the NBDs cause conformational rearrangements within the transporter that facilitate translocation of the peptides over the ER membrane (31).

We investigated whether CPXV012 affects peptide binding to TAP. An 125I-labeled peptide linked to a photoactivatable cross-linker was incubated with microsomes derived from MJS TAP1-eGFP cells. The cells expressed CPXV012 or the EBV-derived TAP inhibitor BNLF2a, which was previously shown to inhibit peptide binding to TAP (16). After UV cross-linking, TAP1-eGFP was isolated from cell lysates, and 125I-labeled peptide/protein complexes were visualized using phosphoimaging.

In cells expressing CPXV012, radiolabeled peptides were cross-linked to TAP1-eGFP (Fig. 2A, lane 1), indicating that CPXV012 does not prevent peptide binding to TAP. As previously reported, 125I-labeled peptides were not cross-linked to TAP1-eGFP in cells expressing BNLF2a (Fig. 2A, lane 2), but they were able to cross-link to TAP1-eGFP in control cells (Fig. 2A, lane 3) (16).

The next step in the peptide-translocation cycle, ATP binding to TAP, was investigated using an ATP-binding assay (Fig. 2B). Agarose beads coated with immobilized ATP were incubated with digitonin lysates of control cells, cells expressing CPXV012, or cells expressing the TAP inhibitor BNLF2a (16). In addition to peptide binding, BNLF2a reduces ATP binding to TAP (16). Pull-down of ATP-agarose beads yields an ATP-bound fraction and an ATP-unbound supernatant fraction. In control cells, the ATP-bound fraction contained TAP1, TAP2, and tapasin (Fig. 2B, lane 1). In contrast, in the ATP-bound fractions of cells expressing CPXV012 or BNLF2a, the amounts of these PLC proteins were reduced (Fig. 2B, compare lanes 2 and 3 with lane 1), whereas these PLC components were abundantly present in the unbound supernatant of CPXV012- and BNLF2a-expressing cells (Fig. 2B, lanes 5 and 6). These results suggest that CPXV012 inhibits the TAP transport cycle by interfering with ATP binding to TAP.

The ER-luminal domain of CPXV012 is required for inhibition of TAP

CPXV012 is a type II TM protein consisting of a cytosolic domain, a TM domain, and an ER-luminal domain (Fig. 3A) (17). To establish the contribution of these domains to TAP inhibition, CPXV012 variants were generated lacking the cytosolic domain (CPXV012-Δcyt), the ER-luminal domain (CPXV012-ΔER), or the cytosolic and TM domains (i.e., consisting of only the ER-luminal domain [CPXV012-soluble]) (Fig. 3A). To test the functionality of the CPXV012 variants, their effect on MHC I surface expression was assessed by flow cytometry (Fig. 3B, 3C). As expected, MHC I surface expression was reduced on cells expressing wild-type CPXV012 compared with control cells. MHC I surface levels also were decreased on cells expressing CPXV012 lacking its cytosolic tail (CPXV012-Δcyt), although not as efficiently as for wild-type CPXV012. MHC I surface levels were not reduced on cells expressing CPXV012 lacking its ER-luminal domain (CPXV012-ΔER). This suggests that the ER-luminal region of CPXV012 is essential for MHC I downregulation. In line with this, expression of the C-terminal 34 aa of CPXV012 alone (CPXV012-soluble) reduced MHC I surface expression, albeit less efficiently when compared with wild-type CPXV012. The contribution of the TM domain and cytosolic tail of CPXV012 was investigated further by fusing the ER-luminal domain of CPXV012 to amino acid residues 58–88 of TIR. This region encompasses the TM domain of TIR and a cytosolic stretch of similar length as the cytosolic tail of CPXV012. The resulting TIR-CPXV012 chimera reduced MHC I surface expression as effectively as did wild-type CPXV012. These results indicate that the ER-luminal domain of CPXV012 is sufficient for TAP inhibition; the presence of a cytosolic tail and TM domain improves the efficiency of TAP inhibition, possibly by stabilizing the C-terminal domain of CPXV012 and/or localizing it to the ER membrane.

Protein levels of the CPXV012 variants were assessed by immunoblot analysis (Fig. 3D). Compared with wild-type CPXV012, CPXV012-Δcyt and CPXV012-ΔER were expressed at very low levels (Fig. 3D, lanes 3 and 4), whereas CPXV012-soluble was undetectable (Fig. 3D, lane 5). In view of the high eGFP levels observed for the CPXV012-soluble IRES eGFP construct, the low protein
expression is likely caused at a posttranscriptional level. The chimeric TfR-CPXV012 was expressed at levels comparable to those observed for wild-type CPXV012 (Fig. 3D, lane 6). Apparently, very low levels of CPXV012 variants are sufficient for downregulating MHC I, as long as the ER-luminal domain of the viral protein is present.

Next, we evaluated the interaction of the ER-luminal domain of CPXV012 with the PLC in the presence of an irrelevant cytosolic tail and TM domain. Abs directed against tapasin were used to isolate the PLC. The amount of chimeric TfR-CPXV012 detected in association with the PLC was comparable to that of wild-type CPXV012 (Fig. 3D, compare lanes 7 and 9). Thus, the ER-luminal domain of CPXV012 is sufficient for interaction with the PLC.

The combined results show that the ER-luminal domain of CPXV012 binds to TAP and is sufficient to reduce MHC I surface levels.

**Amino acids residues 41–65 of CPXV012 are essential for TAP inhibition**

To further delineate the amino acid residues within the ER-luminal domain of CPXV012 involved in inhibiting TAP activity, small stretches of amino acids of FLAG-tagged CPXV012 were substituted with alanine residues (Fig. 4A). To evaluate whether the CPXV012 variants were functional, the MHC I surface levels of CPXV012-expressing cells were compared with those of control MJS cells, expressing eGFP only (Fig. 4B). CPXV012-Ala1 and CPXV012-Ala7 significantly downregulated MHC I surface expression, like wild-type CPXV012 (Fig. 4B). CPXV012-Ala2, CPXV012-Ala3, and CPXV012-Ala6 failed to reduce MHC I expression, whereas CPXV012-Ala4 and CPXV012-Ala5, if anything, increased MHC I surface expression.
The expression levels of the CPXV012 variants were examined by immunoblot analysis of cell lysates using an anti-FLAG Ab (Fig. 4C). The protein levels of the variants were similar with the exception of CPXV012-Ala4 (Fig. 4C, lane 6), for which expression was lower. CPXV012-Ala4 may be synthesized at a lower rate and/or may be more sensitive to degradation.

Next, we examined the capacity of the CPXV012 variants to associate with the PLC. Cells were lysed in digitonin-containing buffer, and tapasin-specific Abs were used to isolate the PLC. After separation of the proteins by SDS-PAGE, FLAG-specific mAb was used to detect the CPXV012 variants. The variants that were able to abrogate MHC I surface expression also were coisolated with the PLC (CPXV012-Ala1 and CPXV012-Ala7), albeit to a lesser extent than wild-type CPXV012 (Fig. 4C, compare lanes 1, 3, and 9). Variants that failed to downregulate MHC I also were not isolated from the PLC, with the exception of CPXV012-Ala3 (Fig. 4C, lane 5).

These results show that amino acid residues 41–65 of CPXV012 are essential for inhibition of TAP. The failure of CPXV012-Ala3 to inhibit TAP indicates that binding to the PLC alone is not sufficient for MHC I downregulation.

**Membrane interaction of the active domain of CPXV012**

The ER-luminal domain of CPXV012 is crucial for inhibition of peptide transport by TAP. To assess the structural properties of this domain, we synthesized a peptide corresponding to amino acid residues 36–69 of CPXV012 (CPXV01236–69) and investigated the secondary structure of this peptide by CD spectroscopy (Fig. 5A). The far UV CD spectrum of CPXV01236–69 obtained in aqueous MES buffer suggested that the peptide adopts a random coil secondary structure. A higher structural order may be induced by lipid membranes, because >30% of the amino acid residues in CPXV01236–69 are hydrophobic. Therefore, the CD spectrum of CPXV01236–69 was measured in the presence of lipid vesicles consisting of phosphatidylcholine (DOPC) and

**FIGURE 4.** Amino acids residues 41–65 of CPXV012 are essential for TAP inhibition. (A) Schematic overview of CPXV012 substitution variants. Amino acid residues substituted for alanine are indicated in bold. The amino acid residue position is shown below. (B) MHC I surface levels are differentially affected by CPXV012 variants. MHC I surface levels of MJ5 cells expressing control vector, wild-type (wt) CPXV012, or alanine-substitution variants were analyzed by flow cytometry. Mean fluorescence intensity of CPXV012-expressing cells was compared with cells expressing control vector, set at 100%. Mean ± SEM from three independent experiments is shown. (C) CPXV012 variants bind differentially to the PLC. Expression levels of FLAG-tagged CPXV012 variants in total lysates of MJ5 cells were analyzed by immunoblotting using an anti-FLAG Ab (mAb M2; middle panel). The presence of FLAG-CPXV012 variants in the PLC was analyzed by immunoprecipitation of tapasin (mAb gp46-C), followed by immunoblotting using an anti-FLAG Ab (mAb M2; lower panel). Anti-TfR Ab (mAb H68.4) was included as loading control (upper panel). Immunoblots are representative of three independent experiments.

The expression levels of the CPXV012 variants were examined by immunoblot analysis of cell lysates using an anti-FLAG Ab (Fig. 4C). The protein levels of the variants were similar with the exception of CPXV012-Ala4 (Fig. 4C, lane 6), for which expression was lower. CPXV012-Ala4 may be synthesized at a lower rate and/or may be more sensitive to degradation.

Next, we examined the capacity of the CPXV012 variants to associate with the PLC. Cells were lysed in digitonin-containing buffer, and tapasin-specific Abs were used to isolate the PLC. After separation of the proteins by SDS-PAGE, FLAG-specific mAb was used to detect the CPXV012 variants. The variants that were able to abrogate MHC I surface expression also were coisolated with the PLC (CPXV012-Ala1 and CPXV012-Ala7), albeit to a lesser extent than wild-type CPXV012 (Fig. 4C, compare lanes 1, 3, and 9). Variants that failed to downregulate MHC I also were not isolated from the PLC, with the exception of CPXV012-Ala3 (Fig. 4C, lane 5).

These results show that amino acid residues 41–65 of CPXV012 are essential for inhibition of TAP. The failure of CPXV012-Ala3 to inhibit TAP indicates that binding to the PLC alone is not sufficient for MHC I downregulation.

**FIGURE 5.** Membrane interaction of the active domain of CPXV012. (A) CPXV01236–69 forms an α-helical secondary structure in the presence of LUVs composed of DOPC and DOPS (7:3). CD spectrum of the ER-luminal domain of CPXV012 was determined in an aqueous buffer or in the presence of LUVs. Results are representative of three independent experiments. (B) CPXV012 inserts into lipid monolayers of DOPC and DOPS. Surface pressure profile was measured after injecting CPXV01236–69 or DMSO into the lipid monolayer subphase at t = 0 min. Surface pressure was determined using Langmuir monolayers. Results are representative of three independent experiments. (C) Surface pressure increase induced by injecting CPXV01236–69 and alanine-substitution variants into the lipid monolayer subphase. The amino acid sequence of the peptides corresponds to the ER-luminal domain of the alanine-substitution variants (Ala1–7) depicted in Fig. 4A. Mean ± SEM from three independent experiments is shown.
COWPOX VIRUS PROTEIN CPXV012 BLOCKS ATP BINDING TO TAP

phosphatidylinerse (DOPS), which are major constituents of biological membranes (32). In the presence of these lipids, CPXV01236–69 adopted a typical α-helical CD spectrum (Fig. 5A), demonstrating that CPXV01236–69 interacts with lipid membranes. This interaction supports the membrane binding and subsequent acquisition of an α-helical secondary structure by the ER-luminal domain of CPXV012.

To gain further insight into the behavior of CPXV01236–69 in a membranous environment, the surface pressure of Langmuir lipid monolayers was measured in the presence of CPXV01236–69 (Fig. 5B). As for the CD experiments, the monolayers consisted of DOPC and DOPS in a ratio of 7:3 and were formed in an aqueous buffer. The lipid monolayer surface pressure was measured by the Wilhelmy method for ∼30 min after injecting CPXV01236–69 into the monolayer subphase. A shift in the surface pressure was interpreted as penetration of the peptide into the lipid monolayer. The addition of CPXV01236–69 to the monolayer subphase resulted in a rapid and strong increase in surface pressure, even at a biologically relevant initial surface pressure of 35 mN/m (33) (Fig. 5B). These results show that the ER-luminal domain of CPXV012 penetrates lipid monolayers and is in line with the effects observed with the CD spectra.

To investigate whether membrane penetration of CPXV01236–69 correlates with TAP inhibition, peptides were synthesized that correspond to the alanine substitution variants depicted in Fig. 4A. The surface pressure was measured after the addition of these CPXV012-peptides to the monolayer subphase (Fig. 5C). Most variants inserted with high affinity into the DOPC/DOPS monolayer, to levels observed for wild-type CPXV01236–69. An exception was CPXV01236–69-Ala3, which had the lowest insertion capacity of all variants. Intriguingly, CPXV012-Ala3 also was not able to reduce MHC I surface levels, although it still interacted with the PLC (Fig. 4). This suggests that membrane insertion of the ER-luminal part of CPXV012 may be necessary for TAP inhibition. In line with this, the peptides corresponding to CPXV012-Ala1 and CPXV012-Ala7, which are capable of TAP binding and inhibition, induced a high shift in surface pressure, showing a lipid insertion comparable to the wild-type peptide.

In conclusion, the ER-luminal domain of CPXV012 variants that are capable of inhibiting TAP strongly interact with phospholipid membranes. Conversely, a CPXV012 variant that fails to inhibit TAP, but still binds to the PLC, interacts poorly with phospholipid membranes. These findings suggest that interaction with phospholipid membranes is required for TAP inhibition by CPXV012.

Discussion

CPXV dedicates two proteins to evasion of MHC class I–mediated Ag presentation. CPXV203 binds to MHC I and retains these molecules in the ER through a KDEL-like KTEL retention motif present at the C terminus of the viral protein. CPXV012 blocks MHC I peptide loading by interfering with TAP-mediated peptide transport into the ER. We studied the molecular mechanisms of TAP inhibition by CPXV012. We show that CPXV012 binds to the PLC but does not alter the overall integrity of this complex. MHC I are enriched within the PLC, which is likely caused by deficient peptide loading of MHC I that prolongs its interaction with the PLC (34). A similar effect was observed for several other viral TAP inhibitors, including BNLF2a of EBV (35), ICP47 of HSV (36), and UL49.5 of BHV (37).

Our results indicate that CPXV012 inhibits peptide transport by interfering with ATP binding to the NBDs of the TAP complex; peptide binding to TAP is unaffected. Our finding that the ER-luminal domain of CPXV012 is essential for TAP inhibition is in agreement with the previous observations that TAP is not inhibited by the larger CPXV012 homolog D10L of CPXV strains GRI-90 and GER 91-3 (17). The N-terminal 46 aa residues of these D10L proteins have a high level of amino acid sequence homology with the corresponding cytosolic and TM region of CPXV012 (Fig. 6A).

In contrast, the ER-luminal/extracellular domains of the D10L proteins show no homology with the active, ER-luminal domain of CPXV012 (17). The ER-luminal regions of these D10L proteins are extended (Fig. 6A) and make up a C-type lectin-like domain, which is suggested to be a ligand for the NK cell inhibitory receptor NKR-P1 (17). Recently, genome sequences of a number of CPXV strains from clinical isolates have been determined (38). By comparing CPXV012 homologs of these strains and of other published CPXV and orthopoxvirus strains, we identified two major clusters (Fig. 6B). Cluster 1 covers strains encoding the larger CPXV012 homologs with an extended ER-luminal domain encoding a C-type lectin-like domain, including D10L of GRI-90 and GER 91-3 (D10L-like proteins in Fig. 6B); cluster 2 contains strains encoding homologs with a truncated ER-luminal domain, similar to that of CPXV012 (CPXV012-like proteins in Fig. 6B).

A comparison of 41 genes conserved among all known poxviruses revealed that CPXV strains group into three distinct clades (38). Members of these clades are more closely related to variola virus, camelpox virus, and taterapox virus (clade 1), CPXV (clade 2), or vaccinia virus (clade 3) (38). All strains in clade 1 and the majority of the strains in clade 2 encode the truncated CPXV012-like protein, with the exception of the isolates CPXV GRI-91 and CPXV HumLue09/1 (Fig. 6B). The D10L-like homologs encoded by the latter two strains are even further extended in the ER-luminal/extracellular domain compared with the other D10L-like homologs, suggesting a distinct evolutionary path for these two proteins. Other strains encoding D10L-like homologs include all CPXV strains of the vaccinia virus–like clade 3 (Fig. 6B). Furthermore, the distantly related ectromelia virus strain Moscow also encodes a D10L-like homolog. The presence of this homolog in two highly divergent orthopoxvirus species suggests that the CPXV012-like variant appeared later in virus evolution. In line with this, 16 of the 18 most recently isolated CPXV strains encode the CPXV012-like protein, supporting our hypothesis that this homolog has a more recent origin and perhaps is under greater selective pressure than are the D10L-like homologs.

Although the D10L-like variants and CPXV012-like variants lack homology within the ER-luminal domain at the amino acid level (Fig. 6A), alignment of the nucleotide sequence reveals that the genomic regions encoding these variants are highly similar at the nucleotide level (Fig. 6A). Probably, a deletion of 5 nt (underlined in Fig. 6A) within the ER-luminal domain of the larger C-type lectin-like domain-containing D10L homologs resulted in a frameshift leading to translation of the truncated ER-luminal domain present in CPXV012 and its homologs.

The ER-luminal domain of CPXV012 adopts an α-helical structure only in the presence of lipid vesicles. Indeed, prediction of the secondary structure of CPXV012 via I-TASSER suggests the existence of two helices: an N-terminal TM helix and a C-terminal α-helix (Fig. 7A). Experimental data indicate that the active domains of TAP inhibitors US6 and ICP47 also contain an α-helical secondary structure (39–41). Active US6 adopts a complex structure with 20% α-helices, whereas US6 lacking an α-helical structure is inactive (41). Structural data on the cytosolic TAP inhibitor ICP47 revealed that the active domain has a defined secondary structure in an aqueous buffer. However, like CPXV012, this domain adopts an α-helical structure in a lipid environment (40). This structural rearrangement results in high-affinity binding of ICP47 to TAP at the cytosolic interface of the ER membrane and is required for efficient TAP inhibition (39, 40).
The impact of a lipid environment on the secondary structure of CPXV012 36–69 suggests that the ER-luminal domain of CPXV012 interacts with phospholipids prominently present in the ER membrane (32). This interaction was examined further using Langmuir lipid monolayers, which have been used extensively to study lipid–protein interactions (42). The extent of insertion of proteins into Langmuir lipid monolayers is proportional to the increase in surface pressure after addition of the protein to the lipid subphase. The addition of CPXV012 36–69 to the lipid subphase induced a large shift in surface pressure, thus confirming the interaction between CPXV012 36–69 and lipids.

The influence of amino acid composition of the ER-luminal domain of CPXV012 on insertion into lipid membranes was investigated by analyzing the impact of amino acid sequence changes on the interaction with phospholipids. This was done using evolutionary relationships between CPXV012 homologs. The amino acid sequence alignment of CPXV012 of CPXV strain Brighton Red (BR) and D10L of CPXV strain GRI-90 was used to identify the role of specific amino acids in the interaction with phospholipids. The phylogenetic analysis of CPXV012 homologs revealed two distinct groups: Group 1 comprises the longer D10L-like proteins containing a C-type lectin-like domain, whereas group 2 contains proteins with a truncated ER-luminal domain, including CPXV012. The phylogenetic tree was constructed using Jalview from the Barton Group (University of Dundee, Scotland, U.K.) (54).

The impact of a lipid environment on the secondary structure of CPXV012 36–69 suggests that the ER-luminal domain of CPXV012 interacts with phospholipids prominently present in the ER membrane (32). This interaction was examined further using Langmuir lipid monolayers, which have been used extensively to study lipid–protein interactions (42). The extent of insertion of proteins into Langmuir lipid monolayers is proportional to the increase in surface pressure after addition of the protein to the lipid subphase. The addition of CPXV012 36–69 to the lipid subphase induced a large shift in surface pressure, thus confirming the interaction between CPXV012 36–69 and lipids.

The influence of amino acid composition of the ER-luminal domain of CPXV012 on insertion into lipid membranes was investigated by analyzing the impact of amino acid sequence changes on the interaction with phospholipids. This was done using evolutionary relationships between CPXV012 homologs. The amino acid sequence alignment of CPXV012 of CPXV strain Brighton Red (BR) and D10L of CPXV strain GRI-90 was used to identify the role of specific amino acids in the interaction with phospholipids. The phylogenetic analysis of CPXV012 homologs revealed two distinct groups: Group 1 comprises the longer D10L-like proteins containing a C-type lectin-like domain, whereas group 2 contains proteins with a truncated ER-luminal domain, including CPXV012. The phylogenetic tree was constructed using Jalview from the Barton Group (University of Dundee, Scotland, U.K.) (54).
vestigated in more detail by substituting stretches of 5-aa residues for alanines. Most substitutions within CPXV012\textsubscript{36–69} showed no difference in the ability to insert into the lipid monolayer, whereas the CPXV012\textsubscript{36–69}-Ala3 mutant inserted poorly into the lipid membrane. The decreased capacity of this variant to insert into lipid monolayers may be explained by the substitution of tryptophan and tyrosine residues. Tryptophan, in particular, has a strong preference for the interfacial lipid–water region of membranes (43). Therefore, substitution of tryptophan may severely affect the insertion capacity of TM peptides. In many TM domains, including the active domain of the TAP inhibitor ICP47, tryptophan residues are located at the interfacial region, where they serve as a membrane anchor (40, 44–47).

Insertion of the active domain of CPXV012 into the ER membrane may not be crucial for interaction with TAP, because CPXV012\textsubscript{36–69}-Ala3 inserts poorly into the monolayer, whereas the corresponding CPXV012-Ala3 protein is still able to bind to TAP. However, because CPXV012-Ala3 does not inhibit TAP transport, lipid insertion and proper anchoring into the lipid–water interface seem to be important for TAP inhibition.

The interaction between the active domain of CPXV012 and the lipid environment is remarkable, because this domain contains a number of cationic residues that are not likely to penetrate into the hydrophobic core of the ER membrane. Therefore, it is more likely that the active domain of CPXV012 resides at the lipid–water interface of the membrane (Fig. 7B). This would resemble the interaction of antimicrobial peptides with phospholipid membranes. Like CPXV012\textsubscript{36–69}, these peptides are also cationic and form β-helical structures in the presence of lipid membranes (48). These peptides may “snorkel” parallel to the lipid–water interface, with their cationic residues extending toward the more hydrophilic part of the membrane interface (43). The pronounced affinity for a lipid environment suggests that CPXV012 has direct access to the TM domains of TAP. The 10 TM domains of TAP1 and 9 TM of TAP2 are intertwined and form a channel through the ER membrane that facilitates peptide transport. As for other ABC transporters, transport through the TM domains depends on structural rearrangements of the TM helices (22, 30). During the peptide-transport cycle, the TM helices form several conformational intermediates that depend on substrate and ATP binding to cytosolic domains of TAP (22, 49). The communication between the TM helices and the cytosolic domains is bidirectional, because the TM helices can also influence substrate and ATP binding at the cytosolic domains (50, 51). By binding directly to the TM domains of TAP, CPXV012 may lock TAP in an intermediate conformation, thereby preventing ATP binding to the cytosolic NBDs and interrupting the peptide-transport cycle. The human CMV-encoded TAP inhibitor US6, the UL49.5 proteins of EHV-1 and EHV-2, and EBV BNLF2a use a similar strategy as CPXV012, and also block ATP binding to TAP by locking TAP in an intermediate conformation (13). In contrast to CPXV012, US6 does not interact directly with the TM helices of TAP, but it binds to ER-luminal loops of TAP (52). UL49.5 also impedes conformational transitions of TAP, but its mode of interaction with its target is unknown (15). BNLF2a interferes with ATP binding through interaction with cytosolic domains of TAP (53). Apparently, structurally unrelated viral TAP inhibitors interfere with ATP binding by targeting TAP at different sites. Thus, TAP seems to be an Achilles’ heel of the MHC I Ag-presentation pathway.

In conclusion, we propose the following mechanism of viral TAP inhibition. The active domain of CPXV012 mediates the interaction with TAP and is crucial for TAP inhibition. The cytosolic and TM domain of CPXV012 improves the efficiency of the active domain, possibly by stabilizing this domain and/or localizing it to the ER membrane. The ER membrane supports the formation of a secondary structure within the active domain of CPXV012. Our combined findings suggest that this domain interacts with TM helices of TAP at the interfacial region of the ER membrane. By interacting with the PLC, CPXV012 may arrest TAP in a conformational state that allows peptide binding but not the subsequent ATP-dependent peptide translocation, thus effectively preventing Ag presentation by MHC I.

Acknowledgments
We thank Gerrit Spierenburg and Koos Gaiser from the Laboratory of Translational Immunology (University Medical Center Utrecht) for technical assistance with cell sorting. We are grateful to members of the Wiertz Laboratory for helpful discussions.
Disclosures
The authors have no financial conflicts of interest.

References
resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 6: 623–632.
700.
ing the maximum insertion pressure of proteins and peptides in lipid mon-
14718.
28. Geng, J., S. Vissarimasarikan and, M. Raghavan. 2013. Analyses of confor-
mational states of the transporter associated with antigen processing (TAP) protein in a native cellular membrane environment. J. Biol. Chem. 288: 37039–
37047.


